Johnson & Johnson Receivables

Johnson & Johnson (JNJ) currently reports a receivables of $19B as of June 2026. That compares with $18B in the prior-year period — up 6.7% year over year. Use the charts on this page to explore Johnson & Johnson's receivables history and peer comparisons.

Johnson & Johnson's receivables increased from $18B to $19B — a 6.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Johnson & Johnson reported $19B in receivables as of June 2026. That compares with $18B in the prior-year period — up 6.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $19B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Johnson & Johnson, and consider following JNJ for alerts when major investors trade the stock.

Johnson & Johnson is classified in the Healthcare sector. On receivables, it currently shows $19B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JNJ with unrelated industries.